Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A prerecorded presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET. Interested parties can access the presentation via the Events and Presentations section of Protara's website. Protara is focused on developing transformative therapies for cancer and rare diseases, including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 through September 14, 2022.

The prerecorded presentation will become available on-demand on Monday, September 12, 2022 at 7:00 a.m. ET and can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When will Protara Therapeutics present at the H.C. Wainwright conference?

Protara Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

How can I access the Protara Therapeutics presentation?

The presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET on Protara's website.

What is Protara Therapeutics focusing on?

Protara Therapeutics is focused on developing transformative therapies for cancer and rare diseases.

What is TARA-002?

TARA-002 is an investigational cell-based therapy being developed by Protara for non-muscle invasive bladder cancer and lymphatic malformations.

What other therapies is Protara developing?

Protara is also developing IV Choline Chloride, a therapy for intestinal failure-associated liver disease.